Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers (MTC-DOX) Administered by Intrahepatic Delivery Versus Intravenous Doxorubicin for Treatment of Patients With Unresectable Hepatocellular Carcinoma

NCT00034333 is registered in ClinicalTrials.gov with FeRx as lead sponsor.

NCT NCT00034333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00034333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers (MTC-DOX) Administered by Intrahepatic Delivery Versus Intravenous Doxorubicin for Treatment of Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
FeRx
Phase
Phase 2/3
Overall status
Terminated
Start date
March 31, 2002
Completion date
Not reported
Enrollment
240
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular